Trump Budget Request Seeks HHS Cuts, Moves 340B Program Under CMS
What’s happening: The White House budget outline seeks a 12.5% reduction in HHS funding and would move oversight of the 340B drug pricing program to CMS. The proposal continues the administration’s push to restructure HHS while pairing funding cuts with policy reorganization.
Why it matters: Any shift of 340B into CMS could change how hospitals engage with compliance, audits, and reimbursement-related oversight. For health systems that rely on 340B savings to support access and community programs, this is a potentially significant operational and financial development.
Casey Means, Trump’s pick for surgeon general, faces Senate confirmation hearing
What’s happening: Casey Means, President Trump’s nominee for surgeon general, appeared before the Senate HELP Committee for her confirmation hearing after an earlier delay. The nomination has drawn attention because of her alignment with HHS Secretary Robert F. Kennedy Jr.’s “Make America Healthy Again” agenda and scrutiny over her views on vaccines and public health.
Why it matters: The surgeon general role is highly visible and can shape national messaging on prevention, nutrition, vaccines, and chronic disease. For hospital systems, the confirmation could signal a federal communications environment that places more emphasis on lifestyle medicine and more political tension around traditional public health guidance.
Federation of American Hospitals names new CEO with policy expertise
What’s happening: Charlene MacDonald is now leading the Federation of American Hospitals after being named president and CEO effective January 1, 2026, succeeding Chip Kahn. Her appointment puts a new policy-facing leader at the helm of one of the hospital sector’s most influential trade groups.
Why it matters: FAH often plays a central role in shaping federal advocacy on reimbursement, regulation, and hospital operations. A leadership change at the association could affect the tone and priorities of industry advocacy on issues including Medicare payment, site neutrality, and hospital regulation.
Proposed CMS rule would set prior auth deadlines for drugs
What’s happening: CMS has proposed a rule to overhaul drug prior authorization in government insurance plans by setting decision deadlines of 24 hours for urgent requests and 72 hours for standard determinations. The proposal would also require public reporting on approval rates, denial rates, appeal outcomes, and decision timeframes, while advancing electronic prior authorization and FHIR-based standards.
Why it matters: Faster timelines and more standardized electronic workflows could reduce administrative burden for clinicians and pharmacy teams, but they may also require workflow, IT, and payer-relations adjustments. The transparency provisions could create new pressure on plans and help hospitals make a stronger case around patient access delays.
Judge vacates HRSA’s restriction on 340B hospital ‘replenishment models’
What’s happening: A federal judge vacated HRSA’s 2013 restriction on certain 340B hospitals’ use of replenishment models involving group purchasing organizations for initial outpatient drug inventory purchases. The ruling found HRSA had not adequately explained the policy under the Administrative Procedure Act, though it did not settle the underlying legal question and leaves room for the agency to revisit the issue.
Why it matters: The decision could give hospitals short-term flexibility in 340B inventory and purchasing strategies, especially where pharmacy operations are complex. At the same time, the uncertainty means systems should avoid assuming the issue is settled, since HRSA could reissue or revise the policy through a stronger administrative process.
Trump administration targets CON laws, what it means for rural healthcare
What’s happening: The administration is tying at least some Rural Health Transformation funding to state-level policy changes, including eliminating certificate-of-need laws. States seeking a share of the $50 billion program are facing increased pressure to repeal or weaken CON frameworks, with Tennessee highlighted as one example.
Why it matters: CON reform can reshape competitive dynamics by making it easier for ASCs and other outpatient providers to expand. For hospital systems, especially in rural or semi-rural markets, that could mean more pressure on service lines, volume mix, and local market positioning.
Pharma fallout from Iran war won’t end with ceasefire
What’s happening: Axios reports that the Iran conflict has exposed the fragility of pharmaceutical supply chains, with disruptions to air cargo, shipping through the Strait of Hormuz, and broader logistics flows in the Middle East. Even if the ceasefire holds, the effects could include higher generic drug costs, shipping bottlenecks, and disruption to clinical trial logistics.
Why it matters: Hospitals are already operating under margin pressure, and even modest increases in generic drug or supply transportation costs can ripple through pharmacy and supply chain budgets. The story also reinforces the need for contingency planning around drug sourcing, inventory levels, and high-risk treatment categories tied to global logistics.